Financial Survey: Dynavax Technologies Corporation (DVAX) vs. The Competition
Dynavax Technologies Corporation (NASDAQ: DVAX) is one of 292 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Dynavax Technologies Corporation to related companies based on the strength of its profitability, analyst recommendations, dividends, risk, earnings, institutional ownership and valuation.
This table compares Dynavax Technologies Corporation and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Dynavax Technologies Corporation||-1,323.99%||-92.09%||-78.45%|
|Dynavax Technologies Corporation Competitors||-5,527.68%||-454.18%||-42.49%|
Risk & Volatility
Dynavax Technologies Corporation has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Comparatively, Dynavax Technologies Corporation’s peers have a beta of 6.62, suggesting that their average share price is 562% more volatile than the S&P 500.
Insider and Institutional Ownership
60.2% of Dynavax Technologies Corporation shares are owned by institutional investors. Comparatively, 51.3% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 2.9% of Dynavax Technologies Corporation shares are owned by insiders. Comparatively, 16.5% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This is a breakdown of current ratings and price targets for Dynavax Technologies Corporation and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Dynavax Technologies Corporation||0||0||5||0||3.00|
|Dynavax Technologies Corporation Competitors||742||2976||11076||223||2.72|
Dynavax Technologies Corporation currently has a consensus target price of $27.80, suggesting a potential upside of 26.94%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 31.84%. Given Dynavax Technologies Corporation’s peers higher probable upside, analysts clearly believe Dynavax Technologies Corporation has less favorable growth aspects than its peers.
Valuation and Earnings
This table compares Dynavax Technologies Corporation and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Dynavax Technologies Corporation||$7.71 million||-$94.16 million||-8.87|
|Dynavax Technologies Corporation Competitors||$258.58 million||$65.85 million||-7.26|
Dynavax Technologies Corporation’s peers have higher revenue and earnings than Dynavax Technologies Corporation. Dynavax Technologies Corporation is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Dynavax Technologies Corporation peers beat Dynavax Technologies Corporation on 7 of the 12 factors compared.
About Dynavax Technologies Corporation
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its products include HEPLISAV-B, AZD1419, SD-101, DV281, DV230F and DV1001. HEPLISAV-B is an investigational adult hepatitis B vaccine. AZD1419 is being developed for the treatment of asthma. SD-101 is an investigational TLR9 agonist designed to elicit a potent and focused immune response to cancer. DV281 is an investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV230F is indicated for the treatment of Liver Tumors. DV1001 targets TLR 7 and 8 agonist for multiple malignancies. DV230F and DV1001 are in pre-clinical stage of development.
Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.